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elanoma chondroitin sulfate proteoglycan (MCSP)
is an early cell surface melanoma progression
marker implicated in stimulating tumor cell prolif-
eration, migration, and invasion. Focal adhesion kinase
(FAK) plays a pivotal role in integrating growth factor
and adhesion-related signaling pathways, facilitating cell
spreading and migration. Extracellular signal–regulated kinase
(ERK) 1 and 2, implicated in tumor growth and survival,
has also been linked to clinical melanoma progression. We
have cloned the MCSP core protein and expressed it in the
MCSP-negative melanoma cell line WM1552C. Expression
M
 
of MCSP enhances integrin-mediated cell spreading, FAK
phosphorylation, and activation of ERK1/2. MCSP transfec-
tants exhibit extensive MCSP-rich microspikes on adherent
cells, where it also colocalizes with 
 
 
 
4 integrin. Enhanced
activation of FAK and ERK1/2 by MCSP appears to involve
independent mechanisms because inhibition of FAK acti-
vation had no effect on ERK1/2 phosphorylation. These
results indicate that MCSP may facilitate primary melanoma
progression by enhancing the activation of key signaling
pathways important for tumor invasion and growth.
 
Introduction
 
Metastatic melanoma is one of the fastest rising skin cancers
(Houghton and Polsky, 2002; Geller and Annas, 2003).
In certain patient groups, primary melanomas progress to
malignancy via discrete but overlapping stages including
dysplasia, radial growth phase (RGP), invasive vertical growth
phase (VGP), and metastasis. Alterations in cell–cell and
cell–ECM interactions are also associated with these stages
of tumor progression. Changes in the expression or function
of adhesion molecules such as integrins, Mel-CAM/MUC18,
CD44, ICAM-1, cadherins, and cell surface proteoglycans
(PGs) have all been documented in the progression of pri-
mary melanomas (Bogenrieder and Herlyn, 2002; Li et al.,
2002).
Melanoma chondroitin sulfate proteoglycan (MCSP) is
uniformly and abundantly expressed in most human mela-
noma lesions (Ferrone et al., 1988) and has been implicated
in tumor invasion (Iida et al., 2001). MCSP expression is
an ominous prognostic factor in acral letiginous melanoma
(Kageshita et al., 1993) and in nonmelanoma tumors such as
infantile acute myeloid leukemia (Hilden et al., 1997). The
protein can be expressed with or without covalently attached
chondroitin sulfate glycosaminoglycan, and is therefore con-
sidered a “part-time” cell surface PG. Chondroitin sulfate
modification of the core protein has been linked to its ability
to bind the heparin-binding domain of fibronectin (FN;
Iida et al., 1992, 1996). MCSP acts as a coreceptor for 
 
 
 
4
 
 
 
1
integrin to modulate cell adhesion and spreading by mecha-
nisms dependent on the small Rho family GTPase Cdc42
and the adaptor protein p130
 
cas
 
 (p130 crk-associated substrate;
Eisenmann et al., 1999). MCSP is also associated with the
transmembrane matrix metalloproteinase MT3-MMP on
VGP melanoma cells, and in vitro facilitates invasion into
type I collagen gels as well as degradation of denatured type I
collagen (Iida et al., 2001).
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Our findings for MCSP function are complemented by
analyses of NG2, the rat homologue of MCSP, which ap-
pears to be important for cell proliferation and migration
(Burg et al., 1998; Chekenya et al., 1999; Nishiyama, 2001).
NG2 interacts with a variety of ECM components, including
FN, collagens type II, V, and VI, laminin, and tenascin to al-
ter cellular morphology and proliferation (Stallcup, 2002;
Majumdar et al., 2003). Collectively, the available results
support a role for MCSP/NG2 as signal-transducing mole-
cules that initiate or modify intracellular signal cascades im-
portant for cell adhesion, motility, and invasion.
Integrins are a family of heterodimeric adhesion receptors
that mediate both cell–ECM and cell–cell adhesion. Inte-
grins initiate multiple cellular signals that profoundly influ-
ence shape, proliferation, differentiation, invasion, metasta-
sis, apoptosis, and anoikis (Dedhar, 1999; Giancotti and
Ruoslahti, 1999; Juliano, 2002). Altered expression of a
number of integrins has been linked to the progression of
malignant melanoma, and increased expression of 
 
 
 
4
 
 
 
1 in-
tegrin is associated with transformation from RGP to VGP
(Johnson, 1999; Hood and Cheresh, 2002). 
 
 
 
4
 
 
 
1 integrin
binds to the CS1-binding domain of FN (Wayner et al.,
1989; Iida et al., 1992) and to the vascular endothelial cell
adhesion molecule VCAM (Mould et al., 1994). Soluble an-
tagonists of 
 
 
 
4
 
 
 
1 integrin inhibit melanoma metastasis in
animal models, emphasizing the importance of this receptor
in melanoma biology (Danen et al., 1998).
FAK is a major nonreceptor tyrosine kinase activated after
integrin-mediated adhesion to ECM proteins such as FN.
Among other things, FAK serves to integrate signaling path-
ways between growth factor receptors and integrins (Sieg et
al., 2000) and is implicated in facilitating cell survival
and regulating cell spreading, migration, and invasion
(Schlaepfer and Hunter, 1996; Hauck et al., 2002). Interac-
tion between FAK and the cytoplasmic tail of 
 
 
 
1 integrins
results in autophosphorylation of FAK tyrosine 397 (FAK
pY
 
397
 
) that can lead to stimulation of a cell-signaling cascade
that ultimately activates the Ras/MAPK/extracellular signal–
regulated kinase (ERK) pathway in some cells (Guan, 1997;
Sieg et al., 2000). Increased expression or constitutive activa-
tion of FAK correlates with increased invasion and metasta-
sis in many malignancies, including melanoma, emphasizing
a potential link between FAK activation and tumor progres-
sion (Kahana et al., 2002; Hecker and Gladson, 2003).
Integrin-mediated adhesion also impacts on growth fac-
tor–stimulated activation of the ERK/MAPK pathway, a
major effector of tumor cell migration, growth, and survival
(Aplin and Juliano, 1999; Howe et al., 2002). Integrin-
mediated activation of ERK/MAPK can occur through
FAK-dependent and independent mechanisms, although the
exact means of activation are unknown (Lin et al., 1997;
Schlaepfer and Hunter, 1997; Barberis et al., 2000). Consti-
tutive activation of ERK 1 and 2 is associated with more ad-
vanced melanoma tumors, where it promotes anchorage-
independent growth and survival (Mansour et al., 1994;
Conner et al., 2003; Satyamoorthy et al., 2003).
In this report, we have cloned and expressed MCSP in an
RGP human melanoma cell line that lacks endogenous
MCSP. Cells transfected with MCSP exhibited integrin-
mediated cell spreading and markedly enhanced phosphory-
lation of FAK compared with mock transfectants. MCSP-
expressing cells also exhibited a higher basal level of ERK1/2
phosphorylation, which was further increased by engaging
 
 
 
4
 
 
 
1 integrin. Enhanced ERK1/2 phosphorylation ap-
peared to be independent of FAK phosphorylation, as over-
expression of a dominant-negative focal adhesion–related
nonkinase (FRNK) completely inhibited phosphorylation of
endogenous FAK, but had no effect on ERK1/2 phosphory-
lation. MCSP also functions as a coreceptor for 
 
 
 
4
 
 
 
1 inte-
grin, and confocal analysis showed extensive colocalization
between MCSP and the 
 
 
 
4 integrin subunit. Therefore, ele-
vated MCSP expression in early tumors may facilitate mela-
noma progression by enhancing the activation of FAK and
ERK1/2 (as well as other signaling pathways) associated with
tumor progression.
 
Results
 
MCSP participates in cell–ECM interactions and is ex-
pressed on most human melanoma cell lines (Ferrone et al.,
1988). Initially, human melanoma cell lines grown from tu-
mors at various stages of progression (Satyamoorthy et al.,
1997; Eisenmann et al., 1999) were screened for MCSP
expression. Of the fifteen cell lines tested, only one,
WM1552C, which was isolated from a patient with an RGP
tumor, failed to express detectable levels of MCSP mRNA
(Fig. 1). By contrast, another RGP cell line, WM35, ex-
pressed easily detectable MCSP mRNA, as did the invasive
VGP cell line WM1341D and the metastatic cell line
A375SM (Fig. 1). Surface expression of MCSP (or absence
in WM1552C cells) was verified by flow cytometry using
mAb 9.2.27 (unpublished data), which recognizes the core
protein of MCSP.
 
Cloning full-length human MCSP
 
Full-length human MCSP cDNA was generated by RT-
PCR amplification of mRNA isolated from A375SM cells as
described in the Materials and methods. Analysis of the full-
length clone revealed a number of variations in nucleotide
and amino acid sequence compared with previous reports
(Pluschke et al., 1996). Short sequences encompassing the
Figure 1. Expression of MCSP mRNA in melanoma cell lines by 
RT-PCR. Poly(A)
  RNA was isolated from each of the cell lines 
indicated and equal amounts were reverse transcribed (  reverse 
transcriptase), followed by PCR amplification with primers specific 
for MCSP or glyceraldehyde-3-phosphate dehydrogenase (G3PDH), 
as a control. 
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regions of variance were amplified from A375SM, WM35,
and WM1341D cells by RT-PCR to verify that the nucle-
otide variations were not cell line dependent or an artifact of
cloning. We also compared the sequences to the human ge-
nome database and found that, in every case, the human ge-
nome sequence matched that found in our clone. We have
concluded that our MCSP clone more accurately reflects the
sequence of MCSP expressed in human melanomas and
have submitted the complete sequence to GenBank (acces-
sion no. AY359468).
Of the eleven differences found in amino acid sequence
(highlighted in Fig. 2), eight of these changes (H477R,
Y478H, L486P, C631R, H715Q, S716G, T717A, and
L942H) reflect amino acids that are identical to the residue at
the corresponding position in the rat homologue NG2, based
on protein sequence alignment using the Wisconsin GCG
package (Nishiyama et al., 1991; Pluschke et al., 1996). The
other three alterations (E1208R, P1405A, and P1557R) rep-
resent novel changes to the amino acid sequence not previ-
ously reported in either MCSP or NG2. Perhaps the most no-
Figure 2. Partial amino acid sequence alignment of the MCSP cDNA generated from A375SM melanoma cells and the published sequence. 
Highlighted sequences represent revisions of the original sequence (Pluschke et al., 1996). The new and original sequence data are available 
from GenBank/EMBL/DDBJ under accession no. AY359468 and X96753, respectively. Asterisks represent novel amino acid changes not 
previously reported for MCSP or NG2. 
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table change is at residue 631, where arginine has replaced
cysteine, thereby reducing the number of potential disulfide
bridges in the NH
 
2
 
-terminal cysteine region of MCSP. This
change may affect folding of the NH
 
2
 
-terminal portion of the
protein, which includes the laminin-G domains. Other struc-
tural features of the MCSP ectodomain, including the puta-
tive chondroitin sulfate attachment sites and newly defined
CSPG repeats, appear to be unaffected by these changes.
 
Transfected MCSP induces adhesion and spreading 
of melanoma cells
 
WM1552C cells transfected with cDNA encoding the
MCSP core protein were generated as outlined in the Mate-
rials and methods, resulting in a stable population of cells
that was 
 
 
 
95% positive for MCSP. Flow cytometric analy-
sis of MCSP expression on transfected cells revealed levels
similar to those observed on cells expressing endogenous
MCSP (unpublished data). Immunoblotting of total cell ex-
tracts was used to determine if the MCSP core protein was
also expressed as a chondroitin sulfate PG on transfected
cells (Fig. 3 A). Two immunoreactive bands at 
 
 
 
400 and
250 kD were detected in extracts of WM1552C/MCSP
cells, which is similar to what was observed in WM1341D
cells that express endogenous MCSP. The larger mol wt spe-
cies represents core protein modified with chondroitin sul-
fate glycosaminoglycan, as evidenced by sensitivity to treat-
ment with chondroitinase ABC (Fig. 3 A, cABC). The level
of 
 
 
 
4
 
 
 
1 integrin on the surface of WM1552C cells was un-
affected by expression of MCSP when evaluated by flow cy-
tometry (unpublished data).
We have previously used chimeric substrates that can se-
lectively bind 
 
 
 
4
 
 
 
1 integrin (GST-rIIIcs, a minimal FN
fragment containing the CS1 integrin-binding sequence)
and MCSP (using antibody against the extracellular portion
of the MCSP core protein) as a model for ligands (Eisen-
mann et al., 1999). We have also shown that metastatic cells
adherent on CS1 spread when the MCSP core protein was
also engaged (Iida et al., 1995; Eisenmann et al., 1999).
Wells coated with a recombinant GST fusion protein con-
taining the CS1 
 
 
 
4
 
 
 
1 integrin-binding domain of FN
(GST-rIIIcs) promoted high levels of adhesion of both
WM1552C and WM1341D cells (Fig. 3 B). Wells coated
with the anti-MCSP mAb 9.2.27 also supported high adhe-
sion levels of both WM1341D cells and WM1552C/MCSP
transfectants (but not parental or mock WM1552C cells;
Fig. 3 B). MCSP-expressing cells did not significantly spread
on surfaces coated only with integrin-binding (GST-rIIIcs/
IgG
 
2a
 
) or PG-binding (GST/mAb 9.2.27) substrates; how-
ever, chimeric GST-rIIIcs/mAb 9.2.27 (integrin/PG-bind-
ing) surfaces promoted extensive cell spreading (Fig. 3, C
and D).
 
MCSP expression enhances phosphorylation of FAK 
and ERK1/2
 
Because FAK is a key member of integrin-mediated signal-
ing pathways and initial cell spreading is regulated partly
through FAK activity in many cells (Guan, 1997; Schlaepfer
et al., 1999), we tested whether MCSP could induce FAK
activation. WM1341D cells were serum starved overnight
and were then plated on the various surfaces as indicated
(Fig. 4). Engaging integrin alone on surfaces coated with
GST-rIIIcs/IgG
 
2a
 
 caused a modest increase in the level of
FAK pY
 
397
 
 that peaked at 30 min after plating (Fig. 4 A). By
contrast, plating the WM1341D cells onto integrin/PG-
binding substrata resulted in enhanced levels of FAK pY
 
397
 
much greater than those observed in cells adherent only via
 
 
 
4
 
 
 
1 integrin. The kinetics of phosphorylation at FAK Y
 
397
 
were similar on both substrates (Fig. 4 A). Plating cells on
surfaces coated with GST/mAb 9.2.27, used to stimulate
MCSP alone, did not result in increased FAK pY
 
397
 
 (Fig. 4
B), indicating that MCSP does not directly stimulate FAK
phosphorylation.
The ERK/MAPK pathway has been implicated in cell
spreading and is one of the downstream effectors of acti-
vated FAK (Guan, 1997; Schlaepfer et al., 1999). We re-
probed the blots to determine if there is a relationship be-
tween FAK pY
 
397
 
 and ERK1/2 phosphorylation in these
cells. Phosphorylated ERK (pERK) 1/2 was easily detected
in the VGP WM1341D cells (Fig. 4 A); it did not apprecia-
bly vary in these cells during the time course of the assay
Figure 3. MCSP supports adhesion and induces spreading 
of WM1552C/MCSP-transfected cells. (A) WM1552C cells 
were stably transfected with MCSP (WM1552C/MCSP) 
and expression verified by immunoblot. Whole-cell lysates 
from cells incubated  0.5 U/ml cABC were fractionated 
by SDS-PAGE and probed with anti-MCSP core protein 
mAb 9.2.27. (B) Cells were plated in 96-well plates on 
3  g/ml GST, 3  g/ml GST-rIIIcs, 1  g/ml mAb 9.2.27, or 
1  g/ml IgG2a, allowed to adhere for 30 min at 37 C, and 
the number of adherent cells was determined by formazan 
absorbance. Data shown represent the mean of triplicate 
wells,   SD. (C) WM1341D- and (D) WM1552C-trans-
fected cells were serum starved overnight and plated on 
chimeric substrata using the same concentrations as in B. 
Plates were incubated at 37 C for 1 h, washed, fixed, and 
stained as described in the Materials and methods. Cell 
areas of a random 50 cells/well from triplicate wells were 
quantified by tracing the cell border using NIH Image 
software. *, P   0.001 by two-tailed t test. 
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(0–60 min). The level of pERK1/2 was equal in cells plated
on either the integrin- or the integrin/PG-binding substrates
(Fig. 4 A), in contrast to what was observed with FAK phos-
phorylation. Engaging MCSP alone also had no effect on
the level of pERK1/2 in these cells (Fig. 4 B). ERK1/2 is
constitutively activated in suspended WM1341D cells (zero
time point) and was not further phosphorylated after cell ad-
hesion (Fig. 4, A and B). Therefore, FAK activation induced
by adhesion of WM1341D cells does not appear to have an
effect on the level of ERK phosphorylation.
As was observed for the WM1341D cells, WM1552C/
MCSP transfectants exhibited low levels of FAK pY
 
397
 
 when
plated onto the integrin-binding surfaces for 60 min (Fig. 4
C). However, the WM1552C/MCSP transfectants (but not
the parental or mock-transfected cells) showed a robust level
of FAK pY
 
397
 
 when plated onto the integrin/PG-binding
surfaces (Fig. 4 C), similar to what was observed in the
WM1341D cells that express endogenous MCSP (Fig. 4 A).
The WM1552C cells differ from the WM1341D cells
with respect to regulating the levels of ERK1/2 phosphoryla-
tion. WM1552C/MCSP cells in suspension maintained eas-
ily detectable levels of pERK1/2, whereas parental and mock
transfectants exhibited very low levels of pERK1/2 under
suspension conditions (Fig. 4 C, zero time point). Plating of
cells onto the chimeric substrate for 1 h at 37
 
 
 
C resulted
in greater levels of ERK1/2 stimulation within the MCSP
transfectants (Fig. 4 C), which may be due, in part, to the
higher baseline level observed in suspended cells. Elevated
levels of pERK1/2 were not observed in cells plated on sur-
faces that bind only MCSP (Fig. 4 C; GST/mAb 9.2.27),
demonstrating that increased levels of pERK1/2 in cells
plated on the chimeric substrate were related to engagement
of integrin.
 
MCSP enhances FAK activation in cells adherent 
to FN-related ligands
 
Next, we wanted to determine if MCSP expression activated
signal transduction pathways when cells contacted FN-
derived ligands, as FN contains multiple cell adhesion sites
that bind to a number of integrins and cell surface PGs. We
used a low coating concentration (0.5 
 
 
 
g/ml) of a recombi-
Figure 4. MCSP stimulates FAK Y
397 and ERK1/2 phosphorylation 
in melanoma cells. Cells were serum starved overnight and plated 
on various chimeric substrata using the same concentrations 
described in Fig. 3 B. (A) WM1341D cells were allowed to adhere 
to the specified substrata at 37 C for the indicated times, lysed with 
SDS sample buffer, and immunoblotted with total and phosphospe-
cific FAK and ERK1/2 antibodies as indicated. (B) WM1341D cells 
were allowed to adhere to plates coated with mAb 9.2.27 and GST 
for the indicated times at 37 C, lysed in SDS sample buffer, and 
lysates were evaluated by immunoblotting as in A. (C) WM1552C 
parental and transfectant cells were plated on the indicated substrata 
and allowed to adhere for 1 h at 37 C. Cells were lysed in SDS 
sample buffer and analyzed for levels of FAK and ERK1/2 phosphor-
ylation as in A.
Figure 5. Plating on GST-FN51 or FN promotes FAK Y
397 phos-
phorylation. WM1552C/Mock and WM1552C/MCSP cells were 
plated at 37 C in 35-mm Petri dishes coated with 0.5  g/ml GST-
FN51 for the indicated times (A), or with FN for 1 h (B) in SIFM. The 
cells were lysed by addition of SDS sample buffer and the lysates 
were evaluated for FAK and ERK1/2 phosphorylation/expression by 
immunoblotting as indicated. White lines indicate that intervening 
lanes have been spliced out. (C) Serum-starved WM1552C/MCSP 
cells were released and pretreated with 5  g/ml of either anti-MCSP 
mAb 9.2.27 or mAb 149.53 for 30 min at 37 C. Cells were plated 
on FN51-coated dishes (0.5  g/ml) for the indicated times at 37 C, 
lysed in SDS sample buffer, and analyzed by immunoblotting with 
the indicated antibodies. 
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nant FN fragment (GST-FN51) that contains both the hep-
arin-binding domain and multiple CS1 sites for binding
both PG and 
 
 
 
4
 
 
 
1 integrin, respectively. WM1552C/
MCSP cells contacting this fragment exhibit elevated levels
of FAK pY
 
397
 
 within 30 min of plating when compared with
mock counterparts (Fig. 5 A). MCSP transfectants also
showed enhanced FAK phosphorylation when plated on low
coating concentrations of intact FN (Fig. 5 B); however, this
enhanced FAK phosphorylation was not evident when
higher coating concentrations (5.0 and 10.0 
 
 
 
g/ml) of ei-
ther GST-FN51 or FN were used (unpublished data). mAb
9.2.27 (but not mAb 149.53) could inhibit the enhanced
FAK phosphorylation when used as a soluble antagonist
(Fig. 5 C). The epitope for mAb 149.53 has been mapped
to core protein residues 1846–1857 (unpublished data),
whereas that recognized by mAb 9.2.27 appears to be lo-
cated toward the NH
 
2
 
-terminal end of the core protein (un-
published data). These results suggest that a specific do-
main(s) within the extracellular portion of the MCSP core
protein is important for promoting FAK phosphorylation in
melanoma cells. The levels of pERK1/2 were less affected by
adhesion to the GST-FN51 fragment or to intact FN than
to the chimeric substrate (Fig. 5). Furthermore, antibodies
against the MCSP core protein that inhibited enhanced
FAK phosphorylation had no inhibitory effect on pERK1/2
levels in MCSP-expressing cells (Fig. 5 C). These results fur-
ther indicate that the activation of FAK and ERK1/2 is regu-
lated by distinct mechanisms in WM1552C/MCSP cells.
 
MCSP and 
 
 
 
4 integrin colocalize on adherent 
melanoma cells
 
Cells were plated onto surfaces coated with GST-FN51 and
were allowed to adhere and spread for 30 min at RT. After
fixation, both MCSP and 
 
 
 
4 integrin were detected on cell
surfaces using MCSP core protein or 
 
 
 
4 integrin-specific
antibodies, followed by secondary antibodies labeled with
Cy3 (
 
 
 
4 integrin) or FITC (MCSP). The distribution of
these receptors was then evaluated by confocal microscopy
(Fig. 6). Under these conditions, both MCSP and mock-
transfected WM1552C cells adhere and spread extensively
on the GST-FN51 fragment. However, the MCSP-express-
ing cells develop extensive microspike-type structures, con-
sistent with an involvement of Cdc42 in MCSP-related sig-
naling pathways. MCSP was distributed at the tips of these
microspikes and at the basal surface of adherent cells in a
perinuclear fashion (Fig. 6 A). The distribution of 
 
 
 
4 inte-
grin was similar to MCSP, also localizing at microspikes and
in a perinuclear fashion on the basal surface of adherent cells
(Fig. 6 A). Mock-transfected cells also spread extensively;
however, the morphology of the cells was quite distinct from
that of the MCSP-expressing cells, with broader lamellae
that contained a circumferential staining pattern for 
 
 
 
4 inte-
grin (Fig. 6 A). These lamellae also lacked the extensive mi-
crospike formations characteristic of MCSP-expressing cells.
Adherent cells were next scanned in XYZ coordinates, the
Z sections corresponding to the substrate proximal region of
adherent cells extracted and scatter diagrams generated using
the Fluoview™ software colocalization processor as outlined
in the Materials and methods. Images containing pixel pairs
that overlap perfectly are described by a straight line that
transects the scatter diagram at a 45
 
 
 
 slope (Fig. 6 B). Pro-
cessing the data from the MCSP transfectants in this way re-
veals a high degree of colocalization of 
 
 
 
4 integrin and
MCSP core protein in the adherent cells. In contrast, a scat-
ter diagram for cells that express only 
 
 
 
4 integrin shows only
linear distribution of pixels along the y axis, dependent on
the relative intensity of 
 
 
 
4 integrin staining (Fig. 6 B).
 
Impact of FRNK expression on FAK and
ERK1/2 phosphorylation
 
Alternative splicing of FAK leads to expression of a trun-
cated protein that contains the focal adhesion–targeting do-
main, but lacks the catalytic and src-binding domains. This
product, FRNK, represents a naturally expressed COOH-
terminal region of FAK that acts as an inhibitor of FAK
function. We used an adenoviral construct to overexpress
FRNK in melanoma cells expressing endogenous MCSP and
our transfectant cells (Fig. 7). Overnight infection with the
FRNK/GFP adenovirus resulted in robust overexpression of
FRNK in both WM1552C/MCSP and WM1341D cells
(Fig. 7 A). Overexpression of FRNK led to complete inhibi-
tion of FAK Y
 
397
 
 phosphorylation in cells adherent on chi-
meric substrata. By contrast, levels of pERK1/2 in either ad-
herent cell population were unaffected (Fig. 7 A).
Overexpression of FRNK in either the VGP WM1341D
cells (Figs. 7 B) or WM1552C/MCSP transfectants (Fig. 7
C) significantly inhibited cell spreading by 60–75% when
compared with control cells. MCSP distribution was also
dramatically affected by overexpression of FRNK in these
cells (Fig. 7 D). Distribution was more uniform in mock-
Figure 6. MCSP and  4 integrin colocalize upon engage-
ment on GST-FN51. (A) WM1552C/Mock and MCSP cells 
were plated on coverslips coated with 5  g/ml GST-FN51 for 
1 h at 37 C in SIFM, and were then fixed. Cells were double 
stained with polyclonal anti-MCSP antibody (FITC) and 
anti- 4 integrin mAb (Cy3), followed by the appropriate 
secondary antibody as indicated. The colocalization of these 
receptors upon engagement is evident in the merged images 
(yellow). (B) Z sections from the adherent boundary of the 
cell were analyzed for the colocalization of MCSP (FITC) and 
 4 integrin (Cy3) using the Fluoview™ software colocalization 
processor. Pixel pairs demonstrating staining for both receptors 
plot at a 45  angle on the scattergram (WM1552C/MCSP cells), 
whereas pixels staining with only one fluorophore fall along 
the corresponding axis (WM1552C/Mock cells).MCSP enhances FAK and ERK activation in melanoma | Yang et al. 887
infected WM1552C/MCSP cells fully adherent and spread
on GST-FN51–coated surfaces, with MCSP present on the
cell body and the extensive array of microspikes (Fig. 7 D,
Adeno-GFP). In contrast, FRNK expression reduced the
spreading of WM1552C/MCSP cells adherent on GST-
FN51 and also caused MCSP to be distributed in a circum-
ferential manner with reduced microspike formation and ex-
tension (Fig. 7 D, Adeno-FRNK).
Discussion
MCSP (and the rat homologue NG2) are cell surface PGs
implicated in the adhesion, migration, and invasion of tu-
mor cells. MCSP is expressed on the vast majority of mela-
noma lesions and melanoma cell lines (Ferrone et al., 1988),
suggesting that it is an important contributing factor to the
progression of primary tumors. By using defined ligands for
either  4 1 integrin or the MCSP core protein, we have
shown that simultaneous engagement of both  4 1 integrin
and MCSP is required to stimulate cell spreading, suggesting
that MCSP acts as a coreceptor for integrin (Iida et al.,
1992, 1995). The core protein of NG2 can directly bind
certain components of the ECM as well as certain growth
factors (e.g., PDGF and bFGF; Burg et al., 1998; Goretzki
et al., 1999). Several cell-signaling molecules have been im-
plicated in MCSP (NG2)-induced spreading, including
GTPases (e.g., Cdc42, Rac1) and the adaptor protein p130
cas
(Eisenmann et al., 1999; Majumdar et al., 2003).
We have cloned human MCSP from A375SM melanoma
cells and have determined that there are several differences in
amino acid sequence that distinguish our clone from previ-
ous reports (Pluschke et al., 1996). We considered that these
changes might be the results of tumor-specific mutations in
the core protein; however, we have verified our sequence in
multiple human melanoma cell lines, and the amino acid se-
quence we reported also equates to what is found in the hu-
man genome database. The biological/structure significance
of these changes remains to be determined; however, they
are mostly localized to the central rodlike domain of the core
protein that contains a newly predicted structural domain
known as the CSPG repeat (Staub et al., 2002). One note-
worthy change is in residue 631, in which a previously re-
ported cysteine in MCSP is replaced by arginine where it
might affect previously predicted disulfide bridge formation
within the core protein (Pluschke et al., 1996).
Melanoma cells expressing endogenous MCSP or stably
transfected with MCSP failed to spread or exhibit high levels
of FAK pY
397 when plated on surfaces coated with a minimal
integrin-binding ligand. By contrast, chimeric substrates
that also engage MCSP promoted robust spreading and en-
hanced FAK phosphorylation. MCSP appeared to enhance
the extent, rather than the rate, of FAK phosphorylation,
based on a comparison of the kinetics of FAK activation in
cells adherent on the GST-rIIIcs fragment versus the chi-
meric substrate. Because plating cells onto a surface coated
only with anti-MCSP mAb had no detectable effect on FAK
phosphorylation, we conclude that MCSP works as corecep-
tor to enhance  4 1 integrin-mediated FAK activation in
these cells.
Although the chimeric substrate model is useful to isolate
the relative contributions of MCSP and  4 1 integrin, it was
also necessary to determine if cells responded in a similar
manner on ECM-related ligands that are more relevant in
vivo. MCSP-expressing cells exhibited enhanced levels of
FAK pY
397 when adhering to surfaces coated with either
GST-FN51 or intact FN. MCSP-specific antibodies that
recognize distinct determinants on the extracellular portion
of MCSP had a differential effect on FAK phosphorylation
stimulated by adhesion to GST-FN51, indicating that a spe-
cific domain(s) within the extracellular portion of the core
protein is important for enhancing integrin-stimulated FAK
phosphorylation. Importantly, it was necessary to use a low
coating concentration of GST-FN51 or FN to observe the
effects of MCSP on enhancing levels of FAK pY
397. MCSP-
expressing cells in contact with higher concentrations of
these ligands did not exhibit significant elevation in the level
of FAK pY
397 compared with mock transfectants. These re-
sults suggest that one important function of MCSP may be
Figure 7. Overexpression of dominant-negative FAK 
(FRNK) inhibits FAK phosphorylation and MCSP-mediated 
melanoma cell spreading. (A) Cells were infected in SIFM 
with an adenoviral FRNK/GFP construct or an adenoviral 
construct expressing only GFP at 37 C overnight, released, 
and allowed to adhere on plates coated with GST-rIIIcs/
mAb 9.2.27 for 1 h at 37 C. Cell lysates were analyzed for 
tyrosine phosphorylation of FAK Y
397 by immunoblotting. 
(B) WM1341D melanoma cells were infected as in A, 
allowed to spread for 1 h at 37 C in wells coated with 
GST-rIIIcs/mAb 9.2.27 or GST-rIIIcs/IgG2a, and the cell 
areas were measured as described in the Materials and 
methods. (C) WM1552C/Mock and MCSP-transfected 
cells were infected overnight as in A. Cells were plated in 
wells coated with GST-rIIIcs/9.2.27 for 1 h at 37 C, and 
the adherent cells were measured as described in the 
Materials and methods. **, P   0.001 by two-tailed t test. 
(D) WM1552C/MCSP cells infected with either adeno-GFP 
or adeno-FRNK were plated on coverslips coated with 
5  g/ml GST-FN51, fixed, and stained for MCSP. Repre-
sentative images from confocal analysis are shown for 
GFP (green) and MCSP staining (red).888 The Journal of Cell Biology | Volume 165, Number 6, 2004
to amplify signals from the ECM that are normally transmit-
ted by integrins (and possibly other receptors).
MCSP-expressing cells adherent on GST-FN51 demon-
strated a striking morphology relative to mock-transfected
controls. The MCSP-expressing cells exhibited extensive mi-
crospike formation, which has been observed previously in
reports examining subcellular distribution of MCSP (Garri-
gues et al., 1986). Confocal analysis of MCSP-transfected
cells demonstrated that both MCSP and  4 integrin are
localized to the basal surface of adherent cells and on
microspikes that form in response to GST-FN51 ligand.
Although colocalization of MCSP and  4 integrin may en-
hance the efficiency of receptor cooperation, caution must
be exercised to avoid overinterpretation of these data. We
have previously shown that anti-MCSP antibody–coated
beads can stimulate cells to undergo cell spreading when
GST-rIIIcs is coated onto plates, indicating that complete
colocalization of the two receptors may not be required to
stimulate cell spreading (Iida et al., 1995).
The present work has also shown that, although the
WM1552C/Mock cells adhered and spread on high concen-
trations of GST-FN51 fragment, the morphology was quite
different than that exhibited by MCSP-expressing cells. Al-
though these cells failed to spread on GST-rIIIcs, the GST-
FN51 fragment contains multiple cellular recognition sites,
several of which bind  4 1 integrin (Iida et al., 1992;
Sharma et al., 1999). Multiple integrin recognition sites
within GST-FN51 may act as “synergy sites” to stimulate
cell spreading more efficiently than GST-rIIIcs alone. These
results clearly show that the signals triggered by MCSP cause
distinctive changes in the organization of the cytoskeleton
that are not triggered by  4 1 integrin alone.
Overexpressing dominant-negative FRNK in both WM-
1341D cells and WM1552C transfectants inhibited FAK
activation and cell spreading. FRNK also had a striking
effect on the subcellular distribution of MCSP in adherent
cells, causing it to localize in a striking circumferential pat-
tern. Although small GTPases such as Cdc42 are associated
with actin-mediated formation of leading edges in spread-
ing/migrating cells, FAK can facilitate cell spreading in part
by inhibiting the activation of RhoA (Burridge and Chrza-
nowska-Wodnicka, 1996; Wakatsuki et al., 2003). Mela-
noma cells overexpressing FRNK still form microspikes, but
lack the ability to extend their leading edges to the same ex-
tent as mock-infected cells, consistent with a model in which
FRNK interferes with the inhibition of the RhoA/myosin
pathway in these cells (Wakatsuki et al., 2003). It is quite
possible that actin-mediated polymerization, which would
likely be intact in the presence of FRNK, is important for
driving MCSP to the leading edge of adherent cells that are
attempting to spread.
MCSP also enhances the activation of the ERK/MAPK
pathway in WM1552C cells, as detected by an enhanced
level of phosphorylated ERK1/2 within these cells. WM-
1552C/MCSP transfectants show increased levels of
pERK1/2 in suspension, and plating onto either the chi-
meric or integrin-bound substrates led to further stimulation
of pERK1/2. By contrast, cells adherent to surfaces coated
with only anti-MCSP mAb 9.2.27 had low levels of pERK1/2
that were not elevated over those detected in suspended
cells, consistent with the importance of integrins in promot-
ing adhesion-induced elevations of ERK/MAPK phosphory-
lation (Lin et al., 1997; Barberis et al., 2000; Danen and Ya-
mada, 2001).
MCSP also appeared to enhance FAK and ERK1/2 phos-
phorylation by different mechanisms. Simultaneous engage-
ment of both MCSP and  4 1 integrin was required to ob-
tain maximal FAK phosphorylation, whereas enhanced levels
of pERK1/2 within these cells were not affected by chimeric
vs. integrin-only binding substrates. MCSP-induced in-
creases in the level of FAK pY
397 were completely inhibited
by overexpression of FRNK, whereas FRNK had no detect-
able effect on the level of pERK1/2 within these cells. Fur-
thermore, WM1552C/MCSP cells exhibited elevated levels
of pERK1/2 even when in suspension, where there was little
if any activation of FAK. Finally, although soluble mAb
9.2.27 inhibited FAK activation in cells contacting GST-
FN51, it had no effect on the level of pERK1/2 in these cells.
Although links between FAK activation and stimulation of
the RAS/MAPK pathway have been reported (Schlaepfer et
al., 1999), this finding is consistent with the many reports
showing that integrin-mediated activation of MAPK can also
occur via FAK-independent mechanisms (Lin et al., 1997;
Barberis et al., 2000; Danen and Yamada, 2001). Although
the mechanisms by which MCSP enhanced the level of
ERK1/2 phosphorylation under these conditions is not yet
known, the data suggest that it is by mechanisms distinct
from MCSP-enhanced activation of FAK.
In contrast to the WM1552C/MCSP cells, the level of
pERK1/2 within the WM1341D cells was not increased
when these cells were plated onto surfaces coated with inte-
grin-binding ligands. We attribute this to the high level of
pERK1/2 already present in WM1341D cells even when
suspended, as we have previously shown (Neudauer and Mc-
Carthy, 2003). Constitutive activation of the ERK/MAPK
pathway is associated with more advanced melanomas
(Satyamoorthy et al., 2003; Smalley, 2003). The mechanisms
leading to constitutive activation of this pathway are multi-
faceted and can include the expression of autocrine growth
factors or activating mutations within the upstream B-Raf
kinase, the latter of which have been associated with the ma-
jority of human melanomas and melanoma cell lines. Our
findings suggest that expression of MCSP can be an addi-
tional contributing factor to the sustained elevation of ERK/
MAPK signaling within melanoma cells. Sustained activa-
tion of the ERK/MAPK pathway has implications in the
growth and invasion of melanoma cells, suggesting that
MCSP expression may contribute to the progression of pri-
mary tumors.
Although MCSP is highly expressed in both primary and
metastatic lesions (Ferrone et al., 1988), its function in mel-
anoma progression is not well understood. Elevated levels of
activated FAK are found in many tumors, including mela-
noma, and are linked to increased growth, survival, and in-
vasion (Kahana et al., 2002; Hecker and Gladson, 2003).
Constitutive activation of the ERK/MAPK pathway is also
associated with malignant progression of melanomas. The
current results suggest that sustained activation of these
pathways in melanoma may be related in part to overexpres-
sion of MCSP. Our data are consistent with a model inMCSP enhances FAK and ERK activation in melanoma | Yang et al. 889
which MCSP serves to amplify signals from the extracellular
environment that are initiated by other cell surface recep-
tors. In the case of FAK activation, which has been linked in
some cells to integration of both growth factor receptor and
integrin-related pathways, MCSP may function to reduce
the requirement of ligands for these receptors (Sieg et al.,
2000). The results would be to give MCSP-expressing cells a
selective advantage in the dynamic and competitive mi-
croenvironment of a progressing tumor, consistent with ob-
servations documenting the sustained expression of MCSP
in a high portion of early- to late-stage melanomas. A more
complete understanding of mechanisms associated with
MCSP function could provide new therapeutic targets in the
treatment of melanoma patients with advanced primary tu-
mors or malignant disease.
Materials and methods
Cell culture
WM35, WM1552C, and WM1341D human melanoma cells were pro-
vided by Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA). Cells
were maintained in 4:1 MCDB 153/Leibovitz’s L-15 medium supple-
mented with 5  g/ml insulin and 2% FBS. A375SM human melanoma
cells were provided by Dr. Isaiah J. Fidler (M.D. Anderson Hospital Cancer
Center, Houston, TX) and cultured in MEM supplemented with 10% FBS,
MEM vitamin solution, 50  g/ml gentamicin, and 1 mM sodium pyruvate.
Antibodies and reagents
Anti-MCSP mAbs 9.2.27 and 149.53 were developed and characterized as
described previously (Morgan et al., 1981; Giacomini et al., 1983). Other
antibodies were purchased from indicated companies: anti-tubulin from
Oncogene Research Products, anti-FAK pY
397 phosphospecific antibody
from Biosource International, Inc., anti-FAK from Upstate Biotechnology,
anti-phospho p44/42 MAPK (pERK1/2) and anti-p44/42 MAPK (ERK1/2)
from Cell Signaling Technology, Inc., anti- 4 integrin from CHEMICON
International, normal mouse IgG2a and goat anti–mouse IgG FC from ICN
Pharmaceuticals, and FITC donkey anti–rabbit and Cy3-donkey anti–
mouse secondary antibodies from Jackson ImmunoResearch Laboratories.
cABC was purchased from Sigma-Aldrich.
Preparation of pAb against MCSP
Purified MCSP, isolated from placental tissue, was donated by Dr. Robert
C. Spiro (Orquest Inc., Mountain View, CA). pAb against MCSP was gener-
ated by immunizing a 6–8-wk-old female New Zealand White rabbit with
keyhole limpet hemocyanin MCSP protein according to a standard proto-
col. The Ig fraction was separated on DEAE-agarose as described previ-
ously (Iida et al., 1992). Specificity of the antibody was determined by im-
munoprecipitation and immunoblot analysis of A375SM melanoma cells,
a metastatic cell line previously shown to express high levels of MCSP (Iida
et al., 1992, 1995).
Recombinant FN fragments and human FN
The recombinant GST fusion proteins of FN fragment rIIIcs (GST-rIIIcs) and
FN fragment 51 (GST-FN51) were purified as described previously (Eisen-
mann et al., 1999). Human plasma FN was purified as a by-product of fac-
tor VIII production by sequential ion exchange and gelatin affinity chroma-
tography as described previously (McCarthy et al., 1988).
MCSP mRNA expression in melanoma cell lines
mRNA was isolated from human melanoma cell lines using the Oligotex
Direct mRNA Kit (QIAGEN) and quantified with the Ribogreen
® RNA
Quantitation Kit (Molecular Probes, Inc.). Full-length cDNA was generated
with the SuperScript™ Preamplification System (Invitrogen). PCR amplifi-
cation of a 450-bp fragment of MCSP was performed using primers 5 
MCSP middle and 3  MCSP middle (described below).
Generation of full-length MCSP construct
Full-length MCSP cDNA was reverse transcribed from mRNA isolated from
A375SM cells as described above. The MCSP cDNA was amplified by PCR
with the eLONGase
® enzyme mix (Invitrogen). Two halves spanning a
unique BamHI site in the MCSP sequence were amplified, one encompass-
ing bases 1–3511 (primer set A) and the second bases 3061–7011 (primer
set B). Primer set A 5 -CTAGAATTCGATGCAGTCCGGCCGCGGC-
CCCCCACTTC-3  5 -CAGCTGTGACGTGGTAGTGGACCTCATCC-3  (3 
MCSP middle, 5  MCSP EcoRI) and primer set B 5 -CAGACCATCAGCCG-
GATCTTCCATGTG-3  (5  MCSP middle) 5 -GCAGTCTAGATGCCTGTC-
CCTGGCCCGATC-3  (3  MCSP XbaI) PCR fragments were digested with
the appropriate enzymes (BamHI and EcoRI for primer set A, BamHI and
XbaI for primer set B) and were ligated into vector pcDNA 3.1( ) (CLON-
TECH Laboratories, Inc.). The resulting full-length constructs were verified
by sequencing. Sequence for the full-length MCSP is available at Gen-
Bank/EMBL/DDBJ (accession no. AY359468).
Generation of stable transfectants
WM1552C cells were transfected with either vector alone (mock) or vector
containing full-length MCSP using FuGENE™ 6 (Roche). Transfected cells
were selected and maintained by culturing in the presence of 0.25 mg/ml
G418. Cells expressing MCSP were further selected by staining with mAb
9.2.27 followed with Cy3 donkey anti–mouse secondary antibody, and the
Cy3-positive cells were selected and collected on a FACSVantage™ cy-
tometer (Becton Dickinson). Positive cells were collected and cultured in
growth medium supplemented with 0.25 mg/ml G418.
SDS-PAGE and immunoblotting
For detection of MCSP core protein and PG expression, cells were resus-
pended in serum- and insulin-free medium (SIFM) at 10
6 cells/ml and were
incubated at 37 C for 20 min with or without 0.5 U cABC/ml. Cells were
lysed in SDS sample buffer and proteins were fractionated with 6% SDS-
PAGE. For the FAK phosphorylation assay, 35-mm Petri dishes were coated
with 0.5 ml of either GST or GST-rIIIcs (3  g/ml) and purified goat anti–
mouse IgG Fc antibodies (final dilution 1:500). After overnight incubation at
37 C, plates were blocked for 1 h with 0.3% BSA (wt/vol) in PBS and were
then incubated with 1  g/ml mAb 9.2.27 or IgG2a (isotype control) for 2 h at
37 C. Cells were starved overnight, released with 5 mM EDTA in PBS, resus-
pended in SIFM at 10
6 cells/ml, and incubated at 37 C for 30 min with or
without 0.5 U cABC. 3   10
5 cells were then added to each dish and incu-
bated at 37 C for indicated times. 4  SDS sample buffer was added to each
plate and the lysate was passed through a 27-gauge needle to shear DNA.
Immunoblotting was performed using standard techniques.
Cell adhesion and spreading assays
Triplicate wells in Immulon-I microtiter plates (Fisher Scientific) were
coated overnight with 100  l of 3  g/ml GST, GST-rIIIcs, and/or 1:500
goat anti–mouse IgG Fc antibodies in PBS. Plates were blocked for 1 h at
37 C with 150  l SIFM containing 0.3% BSA and 20 mM Hepes (adhesion
medium). Antibody-coated wells were incubated for 2 h at 37 C with 1  g/
ml of either IgG2a or mAb 9.2.27, and were then washed with adhesion
medium to remove unbound substrate. Suspended cells (100  l) at 10
5/ml
in adhesion medium were added to each well, the plates were incubated
at 37 C for 30 min, and the wells were gently washed to remove nonad-
herent cells. The number of adherent cells was determined by formazan
absorbance using the Celltiter 96
® Aqueous Non-radioactive Cell Prolifera-
tion Assay (Promega). Data are presented as the percentage of total input
cells   SD, based on a standard curve. For spreading, adherent cells were
photographed at 400  and cell areas were measured with NIH Image
v1.62. Data shown are the average area of 50 cells/well from triplicate
wells,   SEM.
Confocal microscopy and colocalization scatterplots
Cells were plated on coverslips coated with 5.0  g/ml FN51 for 1 h at
37 C in SIFM, washed twice with PBS, fixed with 4% PFA for 30 min at RT,
and blocked with 1% donkey serum. For dual staining, cells were incu-
bated simultaneously with both primary antibodies for 1 h at RT followed
by washing with PBS. Appropriate secondary antibodies were added and
the coverslips were incubated for 1 h at 37 C. Coverslips were washed
four times in PBS and mounted using Gel/Mount™ mounting media
(Biomeda). A laser-scanning system (FV-500; Olympus) with a 60  plan-
apochromatic oil objective was used to image the samples. Z sections cor-
responding to the region of the cell in closest proximity to the substrate
were extracted from image stacks. Pixels having the same location in the
two images were paired (P1, P2) for analysis and plotted in a scatter dia-
gram defined by grayscale values derived from the source image using the
Fluoview™ software colocalization processor (Olympus).
Adenoviral constructs
A replication-defective adenovirus encoding human FRNK (amplified from
human lung fibroblast CCL-20; American Type Culture Collection) was890 The Journal of Cell Biology | Volume 165, Number 6, 2004
used to overexpress this protein in melanoma cells. FRNK cDNA was sub-
cloned into the BamHI and ClaI sites of pBSKs vector. The FRNK insert was
then subcloned into the MIGR1-HCMV plasmid containing a separate pro-
moter and coding region for GFP. The MIGR1-HCMV expression cassette
containing FRNK/GFP was excised and subcloned into pAxCAwt vector
(TaKaRa) and linearized according to the manufacturer’s instructions. The
linearized pAxCAwt   FRNK was introduced into HEK293 cells, and ade-
novirus-FRNK/GFP was amplified from cell extracts and was purified by
CsCl gradient centrifugation. An adenovirus expressing GFP alone was
used as a control. The multiplicity of viral infection was determined by vi-
ral dilution in HEK293 cells. GFP expression was routinely monitored by
flow cytometry to estimate the level of infection of melanoma cells, which
was 95% or greater.
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